Message #56 From:
Lambo1124 Date: October 15, 2008 10:37:54 PM
CLXN - CLX Medical secures worldwide exclusivrights & Merger with Inspire pharmaceutical & CLXN ascent to the NASDAQ $$$$
CLXN - CLX Medical secures worldwide exclusivrights & Merger with Inspire pharmaceutical & CLXN ascent to the NASDAQ $$$$
Who can buying into USA, quickly purely
In 3 Steps
One hears is himself 1 .) about rumors, who CLXN, CLX Medical the worldwide exclusivrechte the by means of ThyroTest pharmaceutical, of the TyroTec, that should have acquired at that time Founder and should have secured, with the corresponding worldwide patenting, herewith it around a fast test means venereal diseases, a procedure that had been tested of more than 100,000 US American physicians. It was existed have should released became loud, the ThyroTest pharmaceutical all tests, and by the US authorities, for the worldwide paragraph
The officielle PR News are expected this nächse week, which would be revolutionary for the CLX Medical, a milestone in the Firm narrow stacks would be reached, which would become and would become itself also in the shares Performance itself again mirror.
Here are after the present course of 0,0002 US$ over 100,000 percent drinne
First Target courses of 2 US$ are the speech
2 .) Next became loud, that a Merger, sprioch a fusion, with the US of American firm Inspire Pharmacdeutivcals - ISPH: NADSAQ in planning is, with the joint goal daughter firm worldwide paragraph, research & expansions
This is Fact
3.) CLXN - Uplisting at the NASDAQ. On the part of CLXN. CLX Medical, momentarily OTCBB/Pinksheet an ascent is planned to the NASDAQ, will see in the future certainly courses of more than 1 US$
This would become after the present course, after reach the course of 1 US$ correspond, = 5,000,000% ensprechen to a 5000 excavator.
My result: Quickly purely and $$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$
CLX Medical, Inc. Announces Agreement to License Additional Point-of-Care Diagnostic Testing Devices and the Outcome of the HandiLab-C Chlamydia Laboratory Study
2008-10-15 09:43 ET - News Release
MURRIETA, CA -- (MARKET WIRE) -- 10/15/08
CLX Medical, Inc. (OTCBB: CLXN), which is focused on the marketing and distribution of unique medical diagnostic testing products, today announced a letter of intent to license additional medical diagnostic testing devices from Intellect Holdings, Ltd., research and development company focusing on the development of innovative products for the healthcare industry.
In addition to the rapid point-of-care products CLX Medical has targeted to license for marketing and distribution in the United States and worldwide markets, the letter of intent includes an agreement to develop a unique CLIA waivable device for the detection of Chlamydia utilizing Intellect Holdings' proprietary device system.
"As part of CLX Medical's core focus to identify and license or acquire unique medical diagnostic testing products for marketing and distribution in the United States and worldwide markets, we continue to seek additional licensing and acquisition candidates, and the agreement with Intellect Holdings provides another source for products that may be represented by CLX Medical," stated Vera Leonard, chief executive officer of CLX Medical. The letter of intent will also allow CLX to pursue a parallel path in preparing a product for the estimated $300 million CLIA waived Chlamydia market.
The results of the laboratory tests validating the efficacy of the HandiLab-C Chlamydia test were inconclusive. Presumably, the chlamydia organisms grown in human tissue cell cultures failed to generate sufficient enzyme to trigger the response in the testing devices using this type of laboratory testing approach.
"This is certainly a disappointment," stated Vera Leonard, CEO of CLX. "We, and our shareholders, have invested a great deal of resources to capitalize on this very lucrative market opportunity. Our strategy at this time will be to go forward with the ThyroTest® acquisition and focus aggressively on its launch as a means of generating revenue and building value for our shareholders. In the meantime, we will continue our work on the HandiLab-C product as a secondary focus.
"With the letter of intent announced today, we will pursue, in parallel, an alternative technology that we believe could also allow us to pursue the CLIA waived chlamydia testing market. It is possible that this product would be ready for clinical trials sooner and face fewer regulatory hurdles than the HandiLab-C product, so we are pleased to have this alternative available to us," added Ms. Leonard.
